Baolingbao Biology Co.Ltd(002286) 3 on March 22, 2021 annual performance express was released. During the reporting period, the company achieved a total operating revenue of 2.765 billion yuan, a year-on-year increase of 34.58%; The operating profit was 236 million yuan, a year-on-year increase of 288.81%; The net profit attributable to the shareholders of the listed company was 202 million yuan, a year-on-year increase of 304.65%; The basic earnings per share is 0.54 yuan.
The company said that during the reporting period, benefiting from the growth of healthy consumption demand such as Zero sugar and sugar reduction and the effective driving of various operation and management measures of the company, the company steadily promoted the business plan determined at the beginning of the year, enhanced the linkage of various businesses of the company, and further improved the core competitiveness of the company; The market has a strong demand for sugar substitutes. In 2021, the supply and demand of erythritol products of the company were booming, and the price of erythritol products increased significantly compared with the same period in 2020, driving the market demand of other functional sugar products at the same time; In 2021, the 13000 ton erythritol expansion project of the company was completed and reached production capacity, further meeting the market demand of erythritol products and consolidating the market position of the company’s functional sugar head enterprise.
According to the announcement, the total assets of the company at the end of the reporting period were 3.029 billion yuan, an increase of 15.80% over the beginning of the period, and the owner’s equity attributable to shareholders of listed companies was 1.813 billion yuan, an increase of 13.38% over the beginning of the period.
